Abstract
T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) is a co-inhibitory immune checkpoint receptor upregulated on T cells and natural killer cells in multiple solid tumors. Early phase clinical trials have shown antitumor activity of anti-TIGIT monoclonal antibodies (mAbs) + anti-programmed cell death protein 1 (PD-1) mAbs in pts with mNSCLC. OCI is a humanized mAb designed to bind to Fc-intact TIGIT with high affinity and specificity. In China, TIS, an anti-PD-1 mAb, is approved for 2/3L treatment of LA/mNSCLC, and 1L treatment of NSCLC with chemo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
